首页> 外国专利> POSITIVELY CHARGED WATER-SOLUBLE PRODRUGS OF ARYL- AND HETEROARYLPROPIONIC ACIDS WITH VERY FAST SKIN PENETRATION RATE

POSITIVELY CHARGED WATER-SOLUBLE PRODRUGS OF ARYL- AND HETEROARYLPROPIONIC ACIDS WITH VERY FAST SKIN PENETRATION RATE

机译:极快皮肤渗透率的芳基和杂芳基丙酸正电荷型水溶性产物

摘要

The novel positively charged pro-drugs of aryl- and heteroarylpropionic acids in the general formula (1) 'Structure 1' and general formula (2) 'Structure 2' were designed and synthesized. The compounds of the general formula (1) 'Structure 1' and general formula (2) 'Structure 2' indicated above can be prepared from functional derivatives of naproxen, suprofen, a- methyl-(p-chlorobenzoyl)-5-methoxy-2-methylindole 3-acetic acid, flurbiprofen, carprofen, pranoprofen, benoxaprofen, alminoprofen, tiaprofenic acid, pirprofen, zaltoprofen, bermoprofen, loxoprofen, indoprofen, fenclorac, oxaprozin, fenbufen, orpanoxin, ketorolac, clidanac, and related compounds, (for example acid halides or mixed anhydrides), by reaction with suitable alcohols, thiols, or amines. The positively charged amino groups of these pro-drugs not only largely increases the solubility of the drugs, but also bonds to the negative charge on the phosphate head group of membranes and pushes the pro-drug into the cytosol. The results suggest that the pro-drugs diffuses through human skin -100-130 times faster than do their parent drugs. It takes 2-4 hours for naproxen, suprofen, a- methyl-(p-chlorobenzoyl)-5-methoxy-2-methylindole 3-acetic acid, flurbiprofen, carprofen, pranoprofen, benoxaprofen, alminoprofen, tiaprofenic acid, pirprofen, zaltoprofen, bermoprofen, loxoprofen, indoprofen, fenclorac, oxaprozin, fenbufen, orpanoxin, ketorolac, clidanac, and related compounds to reach the peak plasma level when they are taken orally, but these prodrugs only took about 40-50 minutes to reach the peak plasma level when they are taken transdermally. In plasma, more than 90% of these pro-drugs can change back to the drug in a few minutes. The prodrugs can be used medicinally in treating any NS AIAs-treatable conditions in humans or animals. The prodrugs can be administered not only orally, but also transdermally for any kind of medical treatments and avoid most of the side effects of NSAIAs, most notably GI disturbances such as dyspepsia, gastroduodenal bleeding, gastric ulcerations, and gastritis. Controlled transdermal administration systems of the prodrugs enable naproxen, suprofen, a- methyl-(p-chlorobenzoyl)-5-methoxy-2-methylindole 3-acetic acid, flurbiprofen, carprofen, pranoprofen, benoxaprofen, alminoprofen, tiaprofenic acid, pirprofen, zaltoprofen, bermoprofen, loxoprofen, indoprofen, fenclorac, oxaprozin, fenbufen, orpanoxin, ketorolac, clidanac, and related compounds to reach constantly optimal therapeutic blood levels to increase effectiveness and reduce the side effects of NSAIAs. Another great benefit of transdermal administration of these pro-drugs is that administering medication, especially to children, will be much easier.
机译:设计并合成了通式(1)“结构1”和通式(2)“结构2”中的芳基和杂芳基丙酸的新型带正电荷的前药。上面指出的通式(1)“结构1”和通式(2)“结构2”的化合物可以由萘普生,suprofen,α-甲基-(对氯苯甲酰基)-5-甲氧基-的官能衍生物制备。 2-甲基吲哚3-乙酸,氟比洛芬,卡洛芬,普洛洛芬,贝诺沙芬,阿米洛芬,噻洛芬酸,吡罗芬,扎托普洛芬,贝莫洛芬,洛索洛芬,吲哚洛芬,芬克洛拉克,草酸布洛芬,芬布芬,奥帕诺辛,酮可乐酚卤化物或混合酸酐),方法是与适当的醇,硫醇或胺反应。这些前药的带正电荷的氨基基团不仅大大增加了药物的溶解度,而且还与膜的磷酸盐头基团上的负电荷键合并将前药推入细胞质。结果表明,前药在人类皮肤中的扩散速度是其母药的100-130倍。萘普生,舒普洛芬,α-甲基-(对氯苯甲酰基)-5-甲氧基-2-甲基吲哚3-乙酸,氟比洛芬,卡洛芬,普洛洛芬,贝诺沙芬,阿米洛芬,噻洛芬酸,吡洛芬,扎洛特洛芬, bermoprofen,loxoprofen,indoprofen,fenclorac,oxaprozin,fenbufen,orpanoxin,ketorolac,clidanac和相关化合物在口服时达到血浆峰值水平,但这些前药仅需约40-50分钟即可达到血浆峰值水平它们是经皮服用的。在血浆中,超过90%的这些前药可以在几分钟内变回药物。前药可用于治疗人或动物的任何NS AIAs可治疗的疾病。前药不仅可以口服给药,而且可以透皮给药用于任何类型的药物治疗,并且可以避免NSAIAs的大多数副作用,尤其是胃肠道疾病,例如消化不良,胃十二指肠出血,胃溃疡和胃炎。前药的受控透皮给药系统使萘普生,舒普洛芬,α-甲基-(对氯苯甲酰基)-5-甲氧基-2-甲基吲哚3-乙酸,氟比洛芬,卡洛芬,普拉洛芬,贝诺沙芬,阿米洛芬,噻洛芬酸,吡洛芬,扎洛特芬,贝莫洛芬,洛索洛芬,吲哚洛芬,芬克洛拉,奥沙普嗪,芬布芬,甲氧平,酮咯酸,克林达那克和相关化合物可达到最佳的治疗血药水平,以提高疗效并降低NSAIAs的副作用。这些前药的透皮给药的另一个巨大好处是,尤其是对儿童给药更容易。

著录项

  • 公开/公告号EP2054384A4

    专利类型

  • 公开/公告日2010-11-03

    原文格式PDF

  • 申请/专利权人 TECHFIELDS BIOCHEM CO. LTD;YU CHONGXI;

    申请/专利号EP20060795662

  • 发明设计人 YU CHONGXI;XULINA;

    申请日2006-08-15

  • 分类号C07D209/12;C07D209/82;C07D263/57;C07D491/04;

  • 国家 EP

  • 入库时间 2022-08-21 18:37:49

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号